Clearside Biomedical (CLSD, Financial) received a key update from Needham analyst Serge Belanger on May 15, 2025. The analyst has maintained a "Buy" rating on the stock, signaling continued optimism towards the company's prospects despite some adjustments in price expectations.
In a notable revision, Needham has lowered the price target for Clearside Biomedical (CLSD, Financial) from $4.00 to $3.00. This represents a significant decrease of 25% from the previous target. The decision to adjust the price target reflects certain dynamics affecting the company's market position.
Investors and market participants may want to take note of these updates as they could have immediate implications on the stock's trading performance. Although the target price has been adjusted downward, the maintained "Buy" rating indicates confidence in the underlying strengths of Clearside Biomedical (CLSD, Financial).
As the market continues to react to new information, it will be essential to keep an eye on further developments and analyst insights regarding Clearside Biomedical (CLSD, Financial).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Clearside Biomedical Inc (CLSD, Financial) is $5.67 with a high estimate of $8.00 and a low estimate of $4.00. The average target implies an upside of 563.54% from the current price of $0.85. More detailed estimate data can be found on the Clearside Biomedical Inc (CLSD) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Clearside Biomedical Inc's (CLSD, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Clearside Biomedical Inc (CLSD, Financial) in one year is $0.16, suggesting a downside of 81.26% from the current price of $0.854. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Clearside Biomedical Inc (CLSD) Summary page.
